



# New Zealand, 2015

## Global Vaccine Action Plan (GVAP) and Regional framework indicators

Polio-free status sustained	Yes	At least one dose of IPV introduced by end of 2015	Yes
Country achieved MNT elimination	Yes	Increasing trend in domestic expenditure since 2010	Yes
Country verified for measles elimination	No	NITAG established (with administrative/legal basis only)	Yes
Seroprevalence of chronic hepatitis B infection (HBsAg) reduced to < 1% in 5 year olds by 2017	Yes	Functional NITAG (legal basis, TORs, ≥ 5 areas of expertise, ≥ 1 meeting per year, agenda and background docs, disclosure of conflict of interest)	Yes
At least one new or underutilized vaccine introduced since 2010*	Yes	JE vaccine introduced in JE risk areas	Not applicable
DTP3 national immunization coverage ≥ 95% by 2020	92%	Primary series JE vaccine ≥ 90% coverage among children under 15 years old	Not applicable
DTP3 coverage ≥ 90% in at least 90% of districts (proportion of districts with ≥ 90% coverage)	Yes (90%)	Case-based surveillance for invasive bacterial vaccine-preventable disease	No
Sustained DTP3 coverage ≥ 95% for three or more years	No	Case-based surveillance for rotavirus disease	No
DTP dropout rate < 5%	1.08%	Rubella and CRS case-based data submitted to WPRO	No

\* New or underutilized vaccines include Hib, HPV, PCV and RV. IPV and JE are not counted. Otherwise, "Yes (specified)" is indicated to account for other vaccines.

Population		
	JRF	UN*
Total	4 649 700	4 528 526
Births	61 328	59 944
NIP target < 1 year (surviving infants)	61 038	60 083
Source of data for NIP target	Census data	

\* United Nations World Population Prospects: The 2015 Revision

Finance	
Gross national income per capita* (US \$)	\$ 40 080
Line item in budget for vaccines	No
% of vaccines in routine immunization funded by government	100%
% of routine immunization - funded by government	100%
Eligible for GAVI support	No

\* World Bank Open Data

## Reported cases of selected vaccine preventable diseases


Year	Acute flaccid paralysis (AFP)		Measles		Rubella		Congenital rubella syndrome (CRS)		Neonatal tetanus		Total tetanus		Diphtheria		Pertussis	
	Non-polio AFP rate	% adequate specimens	Cases	IR	Cases	IR	Cases	IR	Cases	IR	Cases	IR	Cases	IR	Cases	IR
2011	0.3	33%	597	135.2	22	5.0	0	0.0	0	0.0	0	0.0	0	0.0	1992	45.1
2012	0.9	25%	68	15.2	4	0.9	0	0.0	0	0.0	2	0.0	0	0.0	5598	125.5
2013	1.3	50%	8	1.8	1	0.2	0	0.0	0	0.0	1	0.0	0	0.0	3396	75.4
2014	0.9	38%	280	61.5	4	0.9	0	0.0	0	0.0	0	0.0	2	0.0	1099	24.1
2015	0.8	29%	10	2.2	0	0.0	0	0.0	0	0.0	1	0.0	2	0.0	1168	25.8

Non-polio AFP rate = incidence per 100 000 under 15 years; % adequate specimens = % of AFP cases with 2 specimens within 14 days of paralysis onset  
 IR = incidence rate: for measles and rubella, per 1 000 000 population; for CRS and neonatal tetanus, per 1000 live births; for all others, per 100 000 population. Total tetanus includes neonatal tetanus cases.  
 Population source: United Nations World Population Prospects


## Invasive bacterial disease, rotavirus and japanese encephalitis

Year	Rotavirus diarrhea		Japanese encephalitis		Bacterial meningitis		Bacterial pneumonia	
	Surveillance system type	Confirmed cases	Surveillance system type	Confirmed cases	Surveillance system type	Confirmed cases	Surveillance system type	Confirmed cases
2013					Nationwide	Hib - 1 Pneumo - 26 Meningo - 61	Nationwide	Pneumo - 335
2014					Nationwide	Pneumo - 30 Meningo - 18	Nationwide	Hib - 2 Pneumo - 343
2015						Hib - 1 Pneumo - 28 Meningo - 35		Pneumo - 355

### Confirmed measles cases by month of onset 2011–2015



### Confirmed measles cases by age group and vaccination status, 2014–2015





# New Zealand, 2015

Immunization schedule							
BCG	B	DTP-Hib-HepB-IPV	W6, M3, M5	DTP-IPV	Y4	HPV	Y12
Tdap	Y11	Pneumo_conj	W6, M3, M5, M15	Td	Y45, Y65		
Hib	M15	Rotavirus	W6, M3, M5	MMR	M15, Y4		



B=birth, W=week, M=month, Y=year

Planning	
Multi-year plan (MYP)	Yes
Annual workplan for immunization activities	Yes
Updated wild poliovirus importation and cVDPV response plan	Yes

NIP priority needs	
1. New electronic National Immunization Register	

Safe immunization	
% districts using auto-disable syringes	
System to monitor AEFI	Yes
Number of AEFI	4206
Injection safety policy implemented	No
Disposal methods	Incineration
Injection safety review	No

Delivery of immunization services	
% of population served by outreach	
No. (%) of districts with DTP3 coverage < 80%	0 (0%)
No. (%) of districts with DTP3 coverage ≥ 90%	18 (90%)
No. (%) of districts with MCV1 coverage < 80%	0 (0%)
No. (%) of districts with MCV1 coverage ≥ 90%	17 (85%)
No. (%) of districts with DTP drop-out > 10%	0 (0%)
No. (%) of districts with DTP1–MCV1 drop-out > 10%	



School-based immunization	
Is there a school entry requirement?	No
If no, do schools check immunization status at enrolment?	Yes
What vaccines are required/checked?	
At what school level/year?	Pre-school and Primary
Is routine vaccination given at school?	Yes
Which vaccination?	Tdap, HPV
If yes, is this part of a comprehensive school-health program that delivers other health interventions?	Yes

Surveys		
	Coverage survey	Serosurvey
Most recent (year)		2014
Type		Measles and rubella
Geographical representativeness		National
Result		

Measles and rubella elimination			
Confirmed measles case rate* (per 1 million population)	2.9	Year of MCV1 introduction	1969
Confirmed rubella case rate* (per 1 million population)	No data	Year of MCV2 introduction	1992
Discarded as non-measles rate* (Target: ≥ 2 per 100 000 population)	0.5	Year of RCV introduction	1990
% suspected cases with adequate specimens* (Target: ≥ 80%)	No data	Surveillance conducted for CRS	Yes (unknown coverage)
Imported measles cases*	0	Antigens, year and target population of last SIA	M - 1997 (2-10 yrs)
Measles cases with unknown source of infection*	13	Number vaccinated (SIA coverage)	300 000 (75%)

\* Data from measles monthly country reports to WHO

Hepatitis B control			
Year HepB3 vaccine introduced nationwide	1985	Systems to deliver HepB vaccine birth dose	Hospitals, health centers, home
Year HepB birth dose introduced		HBsAg results assessed for blood donors	No
HepB birth dose (within 24 hours) coverage		Policy for screening of pregnant women	Yes
HepB birth dose (within and after 24 hours) coverage		Policy to vaccinate health care workers	Yes